|
|
News Breaks
|
November 17, 2009
|
| 07:11 EDT |  | YMI |
| theflyonthewall.com: | YM BioSciences' CYT997 able to produce disrupting effects in tumors | | YM BioSciences Inc. announced that preclinical results for CYT997 were presented Tuesday in a poster by Cytopia Limited at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts. CYT997 is an orally available, small molecule vascular disrupting agent, or VDA, currently in Phase II clinical studies. The results reportedly demonstrate that when administered metronomically, in frequent, low doses, CYT997 is able to produce potent vascular disrupting effects in tumors in the colon adenocarcinoma xenograft model, and in combination with cisplatin dosed weekly leads to enhanced antitumor effects compared to cisplatin alone. Administration of CYT997 reportedly resulted in a time and concentration-dependent shutdown of tumor vasculature. Daily administration of CYT997 reportedly resulted in a sustained shutdown of tumour vasculature, increased necrosis and increased survival. :theflyonthewall.com |
|
|
News For YMI From The Last 14 Days Check below for free stories on YMI the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 9, 2012
|
| 07:11 EDT |  | YMI |
|
|
|
|
|
Subscribe for More Information